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Abstract
DNA vaccines can be manufactured cheaply, easily and rapidly and have performed well in
pre-clinical animal studies. However, clinical trials have so far been disappointing, failing to
evoke a strong immune response, possibly due to poor antigen expression. To improve
antigen expression, improved technology to monitor DNA vaccine transfection efficiency is
required. In the current study, we compared plasmid encoded tdTomato, mCherry,
Katushka, tdKatushka2 and luciferase as reporter proteins for whole animal in vivo imaging.
The intramuscular, subcutaneous and tattooing routes were compared and electroporation
was used to enhance expression. We observed that overall, fluorescent proteins were not a
good tool to assess expression from DNA plasmids, with a highly heterogeneous response
between animals. Of the proteins used, intramuscular delivery of DNA encoding either tdTo-
mato or luciferase gave the clearest signal, with some Katushka and tdKatushka2 signal
observed. Subcutaneous delivery was weakly visible and nothing was observed following
DNA tattooing. DNA encoding haemagglutinin was used to determine whether immune
responses mirrored visible expression levels. A protective immune response against H1N1
influenza was induced by all routes, even after a single dose of DNA, though qualitative dif-
ferences were observed, with tattooing leading to high antibody responses and subcutane-
ous DNA leading to high CD8 responses. We conclude that of the reporter proteins used,
expression from DNA plasmids can best be assessed using tdTomato or luciferase. But, the
disconnect between visible expression level and immunogenicity suggests that in vivo
whole animal imaging of fluorescent proteins has limited utility for predicting DNA vaccine
efficacy.
Introduction
The use of DNA encoding antigen as a vaccine has many attractive features [1]. These include
ease and speed of antigen development, temperature stability of the vaccine and similar pat-
terns of post-translational modification to intracellular pathogens [2]. The ease of development
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of DNA vaccines is especially of interest for viral pathogens, for example influenza, that require
regular updating to match circulating strains or rapid development to prevent fast spreading
pandemics. However, whilst extremely effective in small animal models, DNA vaccines have
failed to realise their potential in human clinical trials [3]. One factor limiting the progression
of DNA vaccines into the clinic may be poor expression levels in human tissue after immunisa-
tion [4,5].
One approach to understand and improve DNA vaccine delivery is to track expression in
vivo using fluorescent proteins. Since the discovery and development of green fluorescent pro-
tein [6], there has been a rainbow explosion of available proteins [7]. Fluorescent proteins have
a number of characteristics that affect their efficacy as in vivomarkers of expression, including
wavelength, brightness and structure. The excitation and emission wavelengths of the protein
used affects background fluorescence, blue or green fluorescent proteins tend to have higher
levels of background because skin reflects light in the shorter/blue wavelengths of the spectrum,
as an adaptation to protect against UV induced DNA damage [8]. To reduce background, fluo-
rescent proteins have been designed in the red and far-red spectra [9–11], which promise better
signal to noise ratios. A wider gap between excitation and emission can also reduce background
by reducing the acquisition of reflected light from the excitation beam. The brightness (degree
of fluorescence of the protein) is a function of a number of factors including the quantum yield
—the ratio of the number of photons emitted to the number of photons absorbed (the maxi-
mum is 1.0); expression maturation and the extinction coefficient—a measure of how strongly
the protein absorbs light at a given wavelength. The structure of the protein, particularly
whether it is a monomer, dimer or tandem dimer can affect its behaviour in vivo and also has
an effect on the cloning of the proteins as tandem repeats may make conventional PCR
approaches challenging.
However, most of the studies used to characterise fluorescent proteins in vivo have either
imaged injected cells overexpressing the protein [12] or directly injected protein [10]. In order
to be a useful tool for the monitoring of gene expression after DNA delivery, the protein needs
to have sufficient signal strength following de novo expression in tissue. The aim of the current
study was to identify an effective red fluorescent protein for tracking DNA transgene expres-
sion in vivo and to explore how expression affects immunogenicity for vaccines. We assessed
four fluorescent proteins (tdTomato, mCherry, Katushka and tdKatushka2) which have a
range of excitation and emission characteristics, brightness and structures. We observed lim-
ited levels of expression in vivo with all the red proteins used, with tdTomato being the stron-
gest. Different delivery routes led to different expression levels, with a stronger fluorescent
signal after intramuscular delivery than subcutaneous or tattooing. The difference in visible
expression levels did not appear to correlate with the outcome of infection following vaccina-
tion, with protection observed against influenza H1N1 infection when a DNA vaccine encod-
ing haemagglutinin was delivered by either the intramuscular, subcutaneous or tattooing
routes. This suggests that in vivo whole animal imaging of fluorescent proteins has limited util-
ity for predicting DNA vaccine efficacy.
Materials and Methods
Plasmids expressing marker proteins
Plasmids expressing fluorescent proteins (Table 1) were obtained from the following commer-
cial sources: tdTomato (Clontech: pCMV-tdTomato), mCherry (Clontech: pLVX-EF1α-IRES-
mCherry), Katushka (Evrogen: pTurboFP635-C), tdKatushka2 (Addgene: 30181/ pTEC22)
and firefly luciferase (Touchlight Genetics Ltd, Leatherhead, UK: proTLx Lux). Plasmids were
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maintained in Escherichia coli strain TOP10 and purified using Endo-Free giga kit (Qiagen,
Manchester, UK).
In vitro characterisation of fluorescent proteins
CHO-K1 (ATCC origin, Virginia, USA) cells were grown in DMEM (Gibco, Invitrogen, Pais-
ley, UK) supplemented with 10% inactivated FCS, L-glutamate and penicillin and streptomy-
cin. 5x105 cells were seeded per well in a 24 well plate. 1μg of each plasmid was incubated for
30 minutes at room temperature with Lipofectamine 2000 Reagent (Invitrogen) before being
added to the wells. In vitro imaging for expression of fluorescence was carried out using a
Nikon Eclipse TE2000-S inverted microscope under bright light and a TxRed filter set (excita-
tion 540–580nm and emission 600–660nm) at 24, 48 and 72 hours post transfection. The cells
were also imaged with the In vivo Imaging System FX Pro (Bruker Biospin, Coventry, UK) and
image analysis performed using Molecular Imaging SE software version 5.02 (Bruker), using
the region of interest function and subtracting the mean of the control transfected wells.
In vivo transfection
All experiments were carried out in accordance with Animals (Scientific Procedures) Act 1986
and the overall study approved by the Imperial College London Local Animal Welfare and Eth-
ical Review Board (AWERB). 6–8 week old female BALB/c mice were purchased from Harlan
(Quarriston, UK). For intramuscular (i.m.) delivery mice were injected with 50μg DNA in the
anterior tibialis muscle of one leg, for subcutaneous (s.c.) delivery 50μg was injected in the epi-
gastric region. Where used, the site was electroporated with a CUY21 EDIT system (BEX,
Tokyo, Japan) with 5 successive 50-msec pulses of 150mV with 100-msec intervals, intramus-
cular electroporation was delivered by a needle type electrode, and subcutaneous electropora-
tion was delivered by paddle electrode. For tattooing, fur was shaved from the leg of the mouse
and each mouse had 10μl of 50μg DNA administered onto the skin and tattooing (Stealth
Rotary Tattoo System, The Tattoo shop, Bolton, UK) was carried out at an oscillation fre-
quency of 100Hz and needle depth of 0.5mm as described in [13], tattoo DNA was delivered
without electroporation.
In vivo imaging
For fluorescent images, on days 3, 5 and 7 after transfection the mice were imaged at excitation
550nm, emission 600nm or excitation 600nm, emission 700nm using the In vivo Imaging Sys-
tem FX Pro (Bruker Biospin, Coventry, UK). Prior to imaging mice were anaesthetised with
inhaled isoflurane. Mice were imaged for 60 seconds. To avoid autofluorescence at the imaging
site, mice were shaved and depilated using a commercially available depilation cream (Veet
sensitive, Reckitt Benckiser, Hull, UK).
Table 1. Fluorescent proteins used in the study.
Protein Excitation maximum (nm) Emission maximum (nm) Quantum yield Extinction coefﬁcient Brightness Structure
tdTomato [9] 554 581 0.69 138000 95 Tandem dimer
mCherry [9] 587 610 0.22 72000 16 Monomer
Katushka [10] 588 635 0.34 65000 22.1 Dimer
tdKatushka2 [11] 588 633 0.37 62500 x 2 25 Tandem Dimer
Values are taken from published studies (as indicated) and http://fccf.salk.edu/ﬂuorochrometable.php.
doi:10.1371/journal.pone.0130375.t001
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For luminescence, after transfection with plasmid encoding luciferase, expression was visu-
alized following intraperitoneal injection of Rediject D-Luciferin (Perkin Elmer, Waltham,
MA, USA) in accordance with manufacturer’s specification. Light emission was measured for 4
minutes without binning and an X-ray was taken for 30 seconds, the two images were overlaid
using MI SE software. Relative luminescence was quantified by using the software’s region of
interest (ROI) analysis function, with background levels set using control, untransfected
animals.
Immune response to influenza infection
Mice were immunized by the intramuscular, subcutaneous and tattooing routes with 5μg DNA
expressing influenza haemagglutinin (HA) from A/England/195/2009. Mice were immunized
in a prime boost regime with immunizations on day 0 and 14 and infection challenge on day
28. Protection against influenza infection following DNA vaccination was assessed as described
previously [14]. H1N1 Influenza strain (A/England/195/2009) was grown in Madin-Darby
Canine Kidney (MDCK) cells, in serum free DMEM supplemented with 1μg/ml trypsin [15].
Mice were infected intranasally with 5x105 PFU influenza virus. Weight was measured daily to
monitor disease severity. The harvesting of lung tissues was carried out as previously described
[16]. Lungs were homogenized through 100μm cell strainers (BD, Oxford, UK) and washed
through with a 1ml volume of RPMI. After the removal of the supernatants, cells were treated
with ACK lysing buffer for 5 minutes and they were resuspended in RPMI. Cell viability was
assessed by trypan blue exclusion, and total cell numbers were counted by disposable multiwell
haemocytometer. For flow cytometry, prior to staining cells were blocked with CD16/32 (Fc
Block, BD). For surface staining antibodies against the surface markers CD4, CD8, CD3, (BD)
and the H-2Kd pentamer for the IYSTVASSL peptide (Proimmune, Oxford, UK) were added
for 30 minutes on ice. Gating for lymphocytes was determined by back gating on CD3/CD8
double positive cells. Cells were analyzed on an LSR Fortessa flow cytometer (BD) collecting
data on at least 50,000 events.
Antigen specific ELISA
Serum antibodies specific to Influenza HA1 were measured using a standardized ELISA, modi-
fied from [17]. MaxiSorp 96-well plates (Nunc) were coated with 100μl of HA1 (A/England/
195/2009, Life Technologies), or a combination of anti-murine lambda and kappa light chain
specific antibodies (AbDSerotec, Oxford, UK) and incubated overnight at 4°C. Plates were
washed and blocked with 1% bovine serum albumin (BSA) in PBS for 1 hour at 37°C. Sera
were diluted in 1% BSA PBS and 100μl was added to each sample well. A titration of IgG stan-
dard was added to the kappa/lambda capture antibody coated wells. Plates were incubated for
1 hour at 37°C and washed before addition of goat anti-mouse IgG-HRP (Southern Biotech,
Cambridge, UK) secondary antibody and incubated for 1 hour at 37°C. Plates were washed and
developed with 50μl/well of KPL SureBlue TMB substrate (Insight Biotechnology, UK). The
reaction was stopped after 5 min by adding 50μl/well 1 M H2SO4, and the absorbance read at
450 nm on a FLUOstar spectrophotometer (BMG LABTECH GmbH, Ortenberg, Germany).
Absorbance values for the standard titration were fitted with a four parameter logistic curve
and unknown values were interpolated using BMG Omega software.
Statistical analysis
The appropriate statistical test was performed using GraphPad prism 5.01 (GraphPad Software
Inc., La Jolla, CA, USA). Based on the type of data either a 2 way ANOVA with Bonferroni’s
post test or a student’s T-test was performed.
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Results
tdTomato yields the brightest response after in vitro transfection
We selected four fluorescent proteins with a range of excitation and emission characteristics,
brightness and structures in the yellow-red range for assessment in this study (Table 1). The
proteins selected were tdTomato, mCherry, Katushka and tdKatushka2. To initially screen for
visible expression, we compared fluorescence after transfection of CHO-k1 cells in vitro over a
six day time course. Cells were imaged using a Nikon Eclipse TE2000-S inverted microscope
under bright light and a TxRed filter set (excitation 540–580nm and emission 600–660nm)
(Fig 1a). All the proteins tested induced expression of red fluorescence detectable by
Fig 1. Comparison of red fluorescent proteins in vitro. CHO-k1 cells were transfected with 1μg DNA complexed with Lipofectamine. At various time
points, cells were imaged by fluorescent microscopy—excitation 540–580nm and emission 600–660nm (a). Fluorescence intensity was measured by image
analysis software at 550–600 nm (b) or 600–700 nm (c). Images in (a) representative of n = 3 experiments, points in b and c represent mean +/- SEM of 4
repeats, *** p<0.001 comparing tdTomato and other proteins in panel b, ## p<0.01 comparing tdKatushka2 and other proteins in panel c, by 2 way ANOVA.
doi:10.1371/journal.pone.0130375.g001
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microscopy, with a suggestion that tdTomato was brighter, however the excitation wavelength
range used for microscopy was probably favourable to tdTomato. To more directly compare
expression at appropriate wavelengths macroscopic images of the plates were taken using a
Bruker In-VivoMS FX Pro system at excitation 550nm and emission 600nm and quantified
using imaging software (Fig 1b). Wells transfected with tdTomato were significantly brighter
than those transfected with other proteins (p<0.001). When the plates were imaged at a higher
fluorescence excitation (600nm) and emission (700nm) wavelength (Fig 1c), increased signal
was observed for the red-shifted protein tdKatushka2, with significantly greater response than
tdTomato at 120 and 144 hours after transfection (p<0.01). However the total intensity was
lower than that observed for tdTomato at the lower wavelength. It was of note that there was a
greater light signal for the tandem dimer tdKatushka2 than the dimer Katushka which may be
because it is expressed more efficiently. Interestingly, the kinetic of the emitted light was differ-
ent between the two wavelengths for unknown reasons.
tdTomato yields the brightest response after in vivo delivery
The proteins were tested in vivo using three routes of delivery, intramuscular, subcutaneous
and intradermal by tattooing of the skin. Delivery of DNA by tattooing of the skin was chosen
as it has been shown to induce strong T and B cell responses [18,19]. The same dose of 50μg
DNA was delivered by each route. Electroporation dramatically increases the expression of
protein after in vivo DNA delivery [20] and was used for the intramuscular and subcutaneous
routes. Animals were imaged at excitation 550nm and emission 600nm on days 3, 5 and 7 after
gene delivery. Signal was detected following intramuscular delivery of DNA in the tdTomato (3
out of 5 animals), tdKatushka2 (3 out of 5 animals) and Katushka (3 out of 5 animals) groups,
but not the mCherry group, of these tdTomato gave the strongest signal (Fig 2). Expression
was only detectable after subcutaneous delivery of tdTomato (3 out of 5 animals, Fig 3) and not
detectable after tattoo delivery (data not depicted). From this we conclude that tdTomato is the
most effective protein for fluorescent imaging when delivered as a gene, but of limited use, with
a number of limitations including heterogeneity of expression between animals in the same
group and high background autofluorescence due to various sources of noise.
Since the signal was weak, even in the tdTomato group, we looked at luminescence as an
alternative method of imaging. This has the advantage of being an enzymatic reaction and
therefore can be amplified, it also has less background because it measures the direct release of
photons rather than reflection of photons at a different wavelength. Luminescence quantifica-
tion following delivery of the firefly luciferase gene has been used in a number of DNA vaccine
studies [14,21]. Luciferase expression was detectable in 4 out of 5 mice after intramuscular
delivery (Fig 4a) but only 1 out of 5 mice after subcutaneous delivery (Fig 4b), no luciferase sig-
nal was detected after tattoo DNA delivery (Fig 4c). Again, expression was quite variable, but
the data suggests that the peak of expression was between 4 and 7 days after transfection (Fig
4d) as seen in previous studies [22].
Immunisation by different routes alters the immune response to infection
We wished to determine whether the level of gene expression estimated by imaging altered the
outcome of DNA immunisation. From the imaging studies we inferred that expression was
greatest after intramuscular injection followed by subcutaneous injection, with minimal
expression after tattooing, the same routes were used in a vaccination study. Mice were immu-
nised with 5μg plasmid DNA expressing haemagglutinin from influenza H1N1 (A/England/
195/2009) via each of the three routes in a prime boost regime (two doses of DNA in total),
prior to intranasal infection with a matched viral strain. Responses were compared to naïve
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Fig 2. Comparison of red fluorescent proteins after intramuscular DNA delivery.Mice were injected i.m.
with 50μg DNA in the anterior tibialis muscle and the site electroporated. At days 3, 5 and 7 after transfection,
mice were imaged in vivo using an Imaging System at 550nm excitation and 600nm emission.
Representative of n = 3 experiments. White circles indicate fluorescent protein expression.
doi:10.1371/journal.pone.0130375.g002
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control mice. All three groups of immunised mice were protected from influenza infection
compared to naive mice, which lost significantly more weight on days 6 and 7 post infection
(Fig 5a). Interestingly there were qualitative differences in the immune response to different
routes of infection. Mice immunised by the tattooing route lost marginally less weight on days
3–6 than the subcutaneously immunised mice. Tattooing and intramuscular immunisation led
Fig 3. Comparison of red fluorescent proteins after subcutaneous DNA delivery.Mice were injected s.
c. with 50μg DNA in the epigastric region and the site electroporated. At days 3, 5 and 7 after transfection,
mice were imaged in vivo using an Imaging System at 550nm excitation and 600nm emission.
Representative of n = 3 experiments. White circles indicate fluorescent protein expression.
doi:10.1371/journal.pone.0130375.g003
Optimizing DNA Vaccines with Red Proteins In Vivo
PLOSONE | DOI:10.1371/journal.pone.0130375 June 19, 2015 8 / 14
to a strong antibody response, and the response after tattooing was significantly greater than
that observed following subcutaneous (Fig 5b). However, there was a greater CD8 T cell
response following subcutaneous immunisation (Fig 5c). Since all groups were protected after
two vaccinations, we investigated whether differences in protection were observed after a single
immunisation. Mice received a single immunisation with 5μg plasmid DNA expressing hae-
magglutinin from influenza H1N1 (A/England/195/2009) via each of the three routes prior to
intranasal infection with influenza. As with the prime boost regime, a single immunisation
with DNA by either of the routes led to protection against influenza infection (Fig 5d). How-
ever the qualitative differences between the routes of delivery were less pronounced after a sin-
gle immunisation (Fig 5e and 5f). Therefore, the measurable level of protein expression by
imaging may not determine the overall outcome of immunisation against influenza, but may
alter the type of response seen.
Discussion
The aim of the study was to compare DNA expression by in vivo imaging as a means to assess
expression levels of DNA vaccines. A key finding was that all fluorescent proteins gave limited,
heterogeneous signal measurable by in vivo imaging. Of the red fluorescent proteins tested in
Fig 4. Comparison of luciferase expression after DNA by various routes. 50μg DNA encoding luciferase was delivered by the i.m., s.c. or tattooing
routes. At various time points after transfection, mice were injected i.p. with Luciferin substrate and imaged in vivo using an Imaging System. Representative
images from day 7 after transfection by the i.m. (a), s.c. (b) and tattoo (c) routes. Relative expression levels were quantified using image analysis software (d),
points represent mean +/- SEM of n = 5 animals.
doi:10.1371/journal.pone.0130375.g004
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this study, tdTomato was the best for in vivo expression studies. This is the first study directly
comparing the in vivo performance of these proteins when expressed from DNA. A previous
comparison of red fluorescent proteins using transfected cells inserted into dead animals via
capillary tubes [23], demonstrated that proteins with emission spectra>600nm are more effec-
tive because the emitted light is not absorbed by the tissues. In comparison, the current study
looked at fluorescent proteins expressed from DNA directly injected into the animal which is
more relevant to studying DNA vaccines (and gene therapy) than using cells that had been
transfected prior to injection. Proteins with red shifted (higher emission) wavelengths did not
give a stronger signal suggesting that brightness is the key variable for this application. There
are other red, far-red and infrared fluorescent proteins available which may yield a stronger sig-
nal in vivo which were not included in this study [24], but none are theoretically as bright as
tdTomato and some of the infrared proteins require the injection of additional cofactors to
fluoresce. Of note, one technical issue with the study is that different promoters were used,
tdTomato and Katushka were on a CMV promoter, mCherry was on an Ef1a promoter and
tdKatushka2 was on a Mycobacterium Strong Promoter, which may affect expression
efficiency.
Even when red proteins are used, there are a number of sources of auto-fluorescent noise
that can occur within the experiment, including faeces, skin, fur and pen used to label the ani-
mals. Careful preparation of the animals and the use of strongly expressing/ fluorescing pro-
teins can reduce this problem, but not completely mitigate it. We investigated whether
Fig 5. Comparison of immunogenicity after DNA by various routes. 5μg DNA encoding H1 haemagglutinin was delivered by the i.m., s.c. or tattooing
routes on days 0 and 14. On day 28, mice were infected with 5x105 H1N1 influenza in 100μL intranasally. Weight loss was monitored following infection (a),
serum HA1 specific IgG (b), and lung influenza specific (pentamer stained) CD8+ T cells (c) were measured on day 7 after infection. In a subsequent study,
mice were immunised with 5μg DNA encoding H1 haemagglutinin delivered by the i.m., s.c. or tattooing routes on days 0 and were infected on day 14 with
5x105 H1N1 influenza in 100μl intranasally. Weight loss was monitored following infection (d), serum HA1 specific IgG (e), and lung influenza specific
(pentamer stained) CD8+ T cells (f) were measured on day 7 after infection. Points represent n = 5 animals +/- SEM (a) or individuals (b, c) +/- SEM. #
p<0.05, ### p<0.001 between control and other groups analysed by 2 way ANOVA (a), * p<0.05, ** p<0.001 as indicated, analysed by one way ANOVA and
post test (b, c).
doi:10.1371/journal.pone.0130375.g005
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luciferase could be a favourable alternative to fluorescent proteins for in vivo expression studies
and it gave a cleaner signal. However, there are some limitations with luciferase including the
requirement for oxygen to catalyse the reaction, which precludes use in deep tissue and the
need to inject a substrate into the animals, which can increase the cost of the study. In the cur-
rent study we used luciferase from firefly, Photinus pyralis, but other brighter and smaller lucif-
erase proteins are being developed which may be more effective in this context including those
derived from the sea pansy, Renilla reniformis and the deep sea shrimp, Oplophorus graciliros-
tris (NanoLuc) [25]. As we have previously seen, [26], there was considerable heterogeneity
between animals in the visible expression levels using either fluorescent or luminescent pro-
teins, which is a further limitation of these approaches.
Of the routes tested, intramuscular DNA delivery gave the greatest signal with both tdTo-
mato and luciferase, suggesting the highest expression level, or at least the best retention of
functional protein. Expression of sufficient functional reporter protein to be measured on the
in vivo imager is most likely to be determined by the cells that take up and express the trans-
gene. DNA delivered to the muscle, most likely enters myocytes which are energy rich, low
turnover cells leading to higher expression levels. DNA delivered via the tattoo route enters the
dermal space (because the depth of the tattoo delivery was 0.5 mm) where it may be taken up
by adipocytes and fibroblasts which are less metabolically active than myocytes or enter antigen
presenting cells which migrate away from the site of transfection and degrade the expressed
antigen for presentation on MHC. Subcutaneous delivered DNA is probably taken up by a mix-
ture of myocytes and adipocytes. A further consideration is that the induction of a cellular
immune response to expressed transgene, leads to the targeting and clearance of transfected
cells, limiting expression after DNA vaccination [27,28]. Reporter proteins also induce a self-
limiting immune response leading to their clearance [29,30], particularly when the same ani-
mals are re-used.
There was a disconnect between observed expression level and immunogenicity, whilst we
observed greater tdTomato and luciferase signal by the intramuscular than the subcutaneous
or tattooing routes, all three routes appeared to be equally protective against influenza infec-
tion. However there were qualitative differences in the immune response. These studies suggest
that the expression level required to induce an immune response is very much less than that
required to be visualised by in vivo imaging. It also suggests that that DNA vaccine efficacy is
more finessed than expression alone. Expression potentially reflects a minimum threshold over
which a DNA vaccine needs to cross (akin to activation energy). In DNA vaccine clinical trials
it is conceivable that the requisite level of expression was not achieved. This is probably due to
scale up issues, both with vaccine volume and vaccine amount [31]. Approaches are being
explored to increase expression in human DNA vaccines, including electroporation [20], novel
formulations [32] and novel DNA constructs [14]. But above a certain expression threshold,
DNA vaccine delivered antigens will act like conventional protein antigens with other factors
affecting the immune response, including antigen design, route of delivery, formulation and
adjuvants. Therefore, attention needs to be paid to enhancing immunogenicity in addition to
improving expression in the target tissue.
In this study we observed a qualitative change in immune response between the different
routes of DNA delivered, with greater antibody responses when DNA was delivered by tattoo-
ing, greater T cell responses with subcutaneous delivery and a balanced response to intramus-
cular delivered DNA. Immunogenicity is affected by a number of factors including expression
level and the types of antigen presenting cells that process the antigen, there are a number of
studies that explore the impact of different populations of antigen presenting cells in different
layers of the skin and the muscle [33]. A broad comparison of the effect of route of delivery of
DNA vaccines in mouse and macaques showed differences between the routes [34]. However,
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a recent clinical trial comparing DNA vaccines delivered by the intramuscular, subcutaneous
or intradermal routes found no difference in immunogenicity, but found mildly greater reacto-
genicity after intradermal or subcutaneous delivery [35]. It was of note that tattoo delivered
DNA gave no visible signalling by imaging, but gave the strongest antibody response. The
induction of antibody responses to DNA vaccines is often poor and it may be due to retention
of the protein in the cell preventing the B cells from encountering the antigen. Tattooing may
induce a small wave of protein expression [18] simultaneously damaging the cells leading to
cell death and release of the protein into a space where it can interact with B cells. As antigen
responses to DNA vaccines in clinical trials have thus far been poor, it would be of interest to
see if tattooing can improve the response in humans. However, as with other DNA vaccine
approaches, there may be issues of scale up into human studies, in murine studies 1 cm2 surface
area represents a considerable proportion of the mouse leg and it is unclear whether a human
vaccine would need to cover a scaled up area for equivalent effect, for example in rhesus
macaques a 30 cm2 area was used [36].
In this study we explored the impact of the expression level and route of delivery on the
immune response to DNA vaccines. We found that tdTomato and luciferase were the best
reporter proteins and that intramuscular delivery led to the greatest expression of transgene.
This may be of value both for DNA vaccine development and also other DNA delivery applica-
tions, for example gene therapy. However, the immunogenicity of the delivered vaccine was
not solely determined by the expression level of the antigen and antigen expression as mea-
sured by in vivo imaging did not predict the intensity of the immune response. Therefore
increasing the immunogenicity of the expressed antigen is therefore also critical in the develop-
ment of an effective DNA vaccine in man.
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